Abstract
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. Although effective, VKAs have unpredictable pharmacological effects, requiring regular coagulation monitoring and dose adjustment to maintain effects within the therapeutic range. The clinical development pathway for novel anticoagulants often involves evaluation of efficacy and safety in a short-term indication, such as the prevention of venous thrombo-embolism (VTE), followed by longer-term VTE treatment studies, and finally chronic indications, including stroke prevention studies in patients with AF. The coagulation pathway provides many targets for novel anticoagulants, including Factor Xa (FXa) and Factor IIa (thrombin). Numerous oral, direct FXa inhibitors are in various stages of clinical development, including rivaroxaban, LY517717, YM150, DU-176b, apixaban, and betrixaban, and are anticipated to overcome the limitations of VKAs. Dabigatran is the only oral direct thrombin inhibitor in late-stage development. Studies of these agents for stroke prevention in patients with AF are planned or ongoing. If approved, they may represent the next generation of anticoagulants, by providing new therapeutic options for stroke prevention in patients with AF.
Highlights
Atrial fibrillation (AF) is the most common significant cardiac arrhythmia and causes considerable morbidity and mortality
Pivotal phase III studies of stroke prevention in patients with AF are yet to be completed for these agents; phase II studies have been reported in some cases, which establish the efficacy and safety of these Factor Xa (FXa) inhibitors for the prevention of venous thrombo-embolism (VTE) after orthopaedic surgery and/or for the treatment of VTE
These findings suggest that these drugs may have the potential to be useful for stroke prevention in patients with AF
Summary
Acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. The coagulation pathway provides many targets for novel anticoagulants, including Factor Xa (FXa) and Factor IIa (thrombin). Dabigatran is the only oral direct thrombin inhibitor in late-stage development Studies of these agents for stroke prevention in patients with AF are planned or ongoing. If approved, they may represent the generation of anticoagulants, by providing new therapeutic options for stroke prevention in patients with AF. Anticoagulant † Atrial fibrillation † Factor Xa inhibitor † Direct thrombin inhibitor † Stroke
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have